--- title: After Two CAR-T Infusions, She Is Finally Ready to Put on Her Backpack and Start School url: "https://www.yyhmedical.com/en/stories/b-all-car-t-recovery" type: Article inLanguage: en-US disease: B-cell Acute Lymphoblastic Leukemia treatment: CAR-T datePublished: 2026-07-19 --- # After Two CAR-T Infusions, She Is Finally Ready to Put on Her Backpack and Start School > After relapse, central nervous system involvement, and sequential CD19/CD22 CAR-T therapy, she completed all planned treatment and is ready for a new chapter in life. Summary: Jiajia was 6 years old when she was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in 2022. Despite prolonged chemotherapy, she later developed bone marrow relapse with central nervous system involvement. In 2024, her family brought her to the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital, where Dr. Jing Pan and her team developed a sequential CD19/CD22 CAR-T treatment strategy, followed by consolidation and maintenance therapy. Her leukemia has remained in remission. In July 2026, Jiajia completed all planned treatment and officially stopped therapy. Her story follows a child with relapsed, difficult-to-treat B-ALL from CAR-T treatment back to school, and highlights the importance of standardized treatment, continued follow-up, and multidisciplinary care in complex hematologic cancers. On July 7, 2026, in the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital, 6-year-old Jiajia underwent her final bone marrow aspiration and lumbar puncture assessment. The results showed that her leukemia remained in remission. That day, she officially completed treatment. More than four years had passed since Jiajia first became ill in May 2022. At last, this long course of treatment had reached an important milestone. It had also been exactly two years since her first CAR-T infusion. But for Jiajia and her family, the journey was never as simple as receiving a single CAR-T infusion. **From Diagnosis to Relapse: Falling Back, Then Finding the Strength to Keep Going** On May 7, 2022, Jiajia became unusually listless and developed fever and retching. Her family took her to a local hospital, where a bone marrow MICM assessment led to a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL). For this young child, it was the beginning of a long and difficult course of treatment. After induction chemotherapy, measurable residual disease (MRD) remained positive. She went through multiple additional rounds of chemotherapy, but the MRD did not turn negative. Her family faced one cycle of hope and disappointment after another. It was only after nearly a year of chemotherapy that MRD finally became negative, giving the family a brief sense of relief after such a long wait. The relief did not last. In March 2024, follow-up testing showed bone marrow MRD relapse, while cerebrospinal fluid testing was also positive, indicating central nervous system involvement by leukemia. Urgent chemotherapy was given at the local hospital, but this time the disease did not go into remission. The news was devastating for Jiajia's family. Watching such a young child endure repeated punctures, infusions, and treatment side effects was heartbreaking. Still, her family held on to hope, waiting for the next treatment to bring a turning point. **A Turning Point: From the Darkest Moment to a Clinic Visit That Changed the Course** When treatment had reached an impasse, Jiajia's parents refused to give up. They read extensively, sought advice wherever they could, and eventually turned to Dr. Jing Pan in the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital. In June 2024, Jiajia's parents brought her to see Dr. Pan for the first time. Dr. Pan carefully reviewed her previous medical records - including the fact that it had taken nearly a year of chemotherapy for MRD to turn negative, and that chemotherapy after relapse had failed to achieve remission - and assessed her current condition. After detailed discussions with the family, the team developed a sequential CD19/CD22 CAR-T strategy tailored to Jiajia's disease characteristics and treatment history. **Cell Therapy Is Not a Single Procedure - It Is an Entire Treatment Journey** CAR-T therapy is sometimes understood as simply receiving a one-time cell infusion. In clinical practice, however, the infusion is only one part of a much longer process. It begins with a comprehensive assessment. The medical team evaluates the patient's current condition, disease status, progression, and previous treatments to determine whether CAR-T is an appropriate option. From there, the treatment plan is developed and adjusted over time, followed by key steps such as cell preparation and infusion. After infusion, patients may experience fever, inflammatory reactions such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and challenges related to immune recovery. Ongoing follow-up is then needed to monitor treatment response and recovery. These stages are closely connected and rarely stand alone. From a patient's perspective, CAR-T is better understood as a treatment journey that unfolds over time, rather than a single procedure. The outcome depends not only on what happens on infusion day, but on the care delivered before and after it. So what is a patient really choosing in this process? Once the full treatment pathway is laid out, the answer becomes clearer: it is not only a particular technology, but the broader clinical capabilities needed to carry that treatment safely and consistently from one stage to the next. Those capabilities include systematic risk assessment and stratification, reliable execution of the treatment pathway at each stage, experience in managing complex complications, and the ability to adjust the pace and direction of care through multidisciplinary collaboration. These strengths may not be obvious at any single point, but they run through the entire treatment process. For complex diseases such as hematologic cancers, the choice is therefore not simply about selecting a technology. It is also about choosing a clinical team that can deliver that technology consistently and take responsibility for the full course of care. **What Is a Patient Really Choosing in This Process?** Once the full treatment pathway is laid out, the answer becomes clearer: the patient is choosing not only a particular technology, but the broader clinical capabilities needed to support treatment from beginning to end. These include systematic risk assessment and stratification, reliable execution at each stage, experience in managing complex complications, and the ability to continually adjust treatment through multidisciplinary collaboration. These strengths may not be obvious at a single point, but they run through the entire process. For complex diseases such as hematologic cancers, the choice is therefore not simply about a technology. It is also about choosing a clinical team that can deliver it consistently and take responsibility for the full course of care. **Sequential Dual-Target Therapy: Two CAR-T Infusions, One Integrated Strategy** After Jiajia transferred to Beijing GoBroad Hospital, her treatment pathway was re-evaluated and redesigned. On June 20, 2024, she received a CD19 CAR-T cell infusion. Fourteen days later, bone marrow and cerebrospinal fluid assessments showed complete remission. As planned, the team then proceeded with CD22 CAR-T therapy to consolidate the response and reduce the risk of relapse. This sequential CD19/CD22 CAR-T strategy is an area of expertise for Dr. Pan's team. It uses two separate infusions targeting two different antigens, with the aim of reducing relapse associated with antigen loss or downregulation after single-target therapy. The approach requires careful timing of the CD22 CAR-T infusion while keeping patient safety at the forefront, so that there is as little opportunity as possible for immune escape of the target antigen. After sequential CAR-T therapy, Jiajia's leukemia remained in sustained remission. Treatment did not end there. Jiajia subsequently received monthly decitabine as consolidation therapy. Based on her previous treatment and individual condition, the team also developed a maintenance chemotherapy plan for her. **July 7, 2026: Two Years After CAR-T, Treatment Officially Ends** On July 7, 2026, Jiajia completed all planned treatment. Bone marrow aspiration and lumbar puncture assessments showed that her leukemia remained in remission. It had been exactly two years since her first CAR-T infusion, and four years and two months since she first became ill. Over those four-plus years, Jiajia went through repeated punctures, rounds of chemotherapy, and cycles of hope and disappointment. Her family also changed along the way - from feeling lost and overwhelmed, to searching everywhere for answers, and finally finding a team they felt they could trust. What they chose was not simply CAR-T technology, but a clinical team and care system capable of delivering it consistently and supporting the entire treatment journey. ![269ef5a3-fb3e-4d1b-ac98-2af2e35bece9.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260912/6b26df8c134972cea2111b3580c191f1_20260912211204.png "6b26df8c134972cea2111b3580c191f1_20260912211204.png")  Later this year, Jiajia will start school. Like any other 6-year-old, she will put on her backpack, walk into a classroom, and begin a new chapter of childhood. The days of punctures, infusions, chemotherapy, and CAR-T can now begin to recede into the past, marked by July 7, 2026 - the day she officially completed treatment, two years after CAR-T. On the Department of Hemato-Oncology & Immunotherapy's CAR-T "Cure Summit" display at Beijing GoBroad Hospital, Jiajia placed her photo at the two-year milestone. The climb begins from the day of infusion: two years marks an important stage of victory, while five years is the milestone they call being truly "free of leukemia." Her family and doctors believe that one day, her photo will make it all the way to the summit. > This content is published with the authorization of the patient and their family, intended solely to share real experiences and health knowledge. It does not constitute a recommendation of any treatment plan or medical diagnostic advice. For specific treatment, please follow the guidance of a professional physician. --- Original (HTML):https://www.yyhmedical.com/en/stories/b-all-car-t-recovery This is a clean Markdown mirror for large language models; the original page is authoritative.